Smith & Nephew’s (SN) “Sector perform” Rating Reaffirmed at Royal Bank Of Canada

Smith & Nephew (LON:SN)‘s stock had its “sector perform” rating reaffirmed by research analysts at Royal Bank Of Canada in a research note issued on Wednesday,Digital Look reports. They currently have a GBX 1,350 price target on the stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 18.53% from the stock’s previous close.

Several other equities research analysts have also weighed in on SN. Berenberg Bank reiterated a “hold” rating and issued a GBX 13 price objective on shares of Smith & Nephew in a research note on Friday, May 1st. UBS Group reissued a “neutral” rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a report on Tuesday, May 5th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,760 target price on shares of Smith & Nephew in a report on Thursday, May 21st. Three investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of GBX 1,382.63.

Smith & Nephew Trading Down 0.7%

SN stock opened at GBX 1,139 on Wednesday. The company has a market cap of £12.49 billion, a price-to-earnings ratio of 41.01, a P/E/G ratio of 0.46 and a beta of 0.67. The firm has a fifty day moving average of GBX 1,163.63 and a 200 day moving average of GBX 1,221.87. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.